Simón Vidal
@SimonVidalV
Followers
297
Following
593
Media
16
Statuses
437
Cellular reprogramming / longevity / Desci
San Diego, CA
Joined February 2013
In 3 days, we'll host ~100 of the top leaders in open science, publishing, and research funding for a full day of dialogue and open networking.
1
13
41
ChatGPT has become extremely frustrating with its safety bullshit. Sometimes I can’t really get any answers when asking simple scientific methodologies. Bye bye ChatGPT and hello 👋 Gemini.
0
0
1
Very cool initiative for a replication study on a peer reviewed paper! Do you think this study will be replicated? https://t.co/d0YrgMxQkz
manifold.markets
79% chance. Context: A recent study in fruit flies tested the hypothesis that accumulation of the Alzheimer’s disease associated peptide Aβ42 disrupts sleep and increases wakefulness. We contracted...
0
0
0
Inspired by this great chat with DeepMind CEO Demis Hassabis, I’ve been thinking about the future of AI in drug discovery. His thoughts starts at min 24:45. Isomorphic, DeepMind’s spinoff, is already working with Novartis and Eli Lilly to apply AI to small molecule and protein
0
0
2
Really sad to see how Fate Therapeutics has lost so much value. At one point it was a $5–6B market cap company, and in just a few years it has come down to only about $100M. I’m still very bullish on induced pluripotent stem cells, but something probably needs to change
0
0
3
What’s the biggest barrier to building something amazing ? Is it capital, talent, timing, or leadership? I believe one of the main obstacles is the prevalence of negativism. Very often I see that new ideas are buried under a list of reasons why they won’t work, rather than
businesshealthmatters.org
To effectively focus on solutions, it's crucial to define clear goals. What do you want to achieve? What outcome are you aiming for?
0
0
6
We need more of this!!
A longevity AI agent (@Aubrai_) is generating hypotheses. Now, they’re being posted on @ResearchHub as funding proposals for scientists to test.
0
0
0
It appears that after ~3.5 years the world can now see something more about one of the most unique companies in the past 10 years :)
0
0
2
Flood gates are opening for peer reviews of funding proposals on @ResearchHub! Interested in pushing open, distributed, incentivized peer reviews at @ResearchHubF? Apply through our editor interest form 👇
20
21
122
Personally, I am still most optimistic about using cellular reprogramming to reshape the immune system and potentially improve health. https://t.co/QG1fdUR0zT
nature.com
Nature Aging - Hofer and colleagues explore how immunosenescence impairs vaccine efficacy in older adults, then review emerging vaccine technologies and gerotherapeutic interventions as strategies...
0
0
2
Improving vaccine efficacy in the elderly is a critical challenge. But could this be pursued as a viable indication for FDA approval? I’m quite excited that longevity interventions like rapamycin and caloric restriction are now being explored to enhance immune function.
1
0
3
A new fMRI study on Wim Hof breathing has reached its funding goal on ResearchHub. It’s the first human trial to test how this breathwork technique might boost brain waste clearance and mental health. 🧵 1/5
45
45
135
And if this is the case, how is that an executive from a large corporation can help when the science of startups often is extremely technical? Would you try to recruit a younger technical person to join the board or you would think that these technical experts
1
0
2
Potentially they can save you a lot of time and money by making suggestions but is this enough? Do startup mostly fail because of execution, strategic decision, science or all the above? I tend to think that they fail mostly because the science didn’t workout
1
0
0
I see quite often that when senior executives (eg ceo, cso etc) retire from large pharma/biotechs, they join the board of directors of startups, and I often wonder how good of a decision this is. I mean i have no doubt that they have seen and experienced a lot in their career.
1
0
1